2 assets in Schwannomatosis

Therapeutic assets addressing Schwannomatosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Immunoglobulin G, Anti-(Human Calcitonin Gene-Related Peptide Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer Schwannomatosis	Massachusetts General Hospital	P2	CCC (53)
Siltuximab Schwannomatosis	Massachusetts General Hospital	P2	CCC (53)